Cargando…
Preparation of monovalent follistatin-like 3-Fc-fusion protein and evaluation of its effects on muscle mass in mice
Follistatin-like 3 (FSTL3) is an endogenous antagonist against transforming growth factor-β family ligands. Monovalent FSTL3-Fc fusion protein (mono-FSTL3-Fc) generated with knobs-into-holes technology overcomes limitations of current anti-myostatin therapies. We have developed a facile protocol for...
Autores principales: | Ozawa, Takayuki, Miyazono, Kohei, Morikawa, Masato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455479/ https://www.ncbi.nlm.nih.gov/pubmed/34585166 http://dx.doi.org/10.1016/j.xpro.2021.100839 |
Ejemplares similares
-
Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice
por: Ozawa, Takayuki, et al.
Publicado: (2021) -
Systemic administration of Follistatin288 increases muscle mass and reduces fat accumulation in mice
por: Gangopadhyay, Samudra S.
Publicado: (2013) -
Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA
por: Schumann, Canan, et al.
Publicado: (2018) -
Are follistatin-like protein 1 and follistatin-like protein 3 associated with inflammatory processes in patients with familial Mediterranean fever?
por: Kaplan, Huseyin, et al.
Publicado: (2023) -
In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
por: Shan, Lu, et al.
Publicado: (2021)